期刊文献+

晚期胃肠肿瘤化疗术式分析

Therapeutic effect comparison different chemotherapy methods for advanced gastric and colorectal carcinoma
暂未订购
导出
摘要 目的:两种不同化疗方法治疗晚期胃肠肿瘤效果评价。方法:74例晚期胃肠肿瘤患者随机分为单一组和联合组,每组37例。单一组给予吡喃阿霉素静脉推注、HCPT静脉滴注、5-Fu静脉滴注及DDP静脉滴注,联合组予以吡喃阿霉素静脉推注、HCPT静脉滴注,5-Fu及DDP腹腔灌注;4个疗程后评价疗效,随诊1~2年。结果:联合组近期有效率为54.05%,不良反应轻,改善乏力、食欲减退方面明显;单一组近期有效率为43.24%,不良反应重(P<0.05)。结论:联合化疗法优势明显,适合临床应用。 Objective To value the therapeutic effect and toxicity of two route chemotherapy and intravenous chemotherapy in advanced gastric and colorectal cancer.Methods All the 74 patients suffering from advanced gastric and colorectal carcinoma were randomized into two groups,37 patients were treated by two route chemotherapy:intravenous chemotherapy with THP and HCPT,and intraperitoneal chemotherapy with 5-Fu and DDP.37 patients were treated by intravenous chemotherapy of THP.HCPT.5Fu and DDP.Each treatment period is 28 days.We have valued the therapeutic effect per two treatment periods at least for 1~2 years.Results The early rate of two route therapeutic effect was 54.05%,The reaction of toxicity was mild.The early rate of intravenous chemotherapeutic effect was 43.24%.The reaction of toxicity was serious(P0.05).Conclusion Two route chemotherapy has more advantages than intra-venous chemotherapy with it's long survival time and mild toxicity.
作者 周智勇
出处 《吉林医学》 CAS 2011年第9期1683-1684,共2页 Jilin Medical Journal
关键词 晚期胃肠肿瘤 化疗 静脉滴注 Nadvanced gastric and colorectal carcinoma Chemotherapy Intravenous drip
  • 相关文献

参考文献3

二级参考文献11

  • 1管忠震,张力,李龙芸,蒋国梁,刘叙仪,储大同,赵洪云,李玮.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J].癌症,2005,24(8):980-984. 被引量:114
  • 2周清华,王瑾,许峰.2005年美国国家综合癌症网(NCCN)非小细胞肺癌临床指南[J].中国肺癌杂志,2005,8(4):332-346. 被引量:77
  • 3张康,左强,罗荣城.吉非替尼治疗36例晚期非小细胞肺癌[J].中国癌症杂志,2006,16(10):878-879. 被引量:15
  • 4Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in ontology[J].J Natl Cancer Inst,1993,85(5) : 365- 376.
  • 5Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise [ J ] .Br J Cancer,1999,79(3-4) : 538-544.
  • 6Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995 [ J ] . Chest,1998,113(2) : 467-481.
  • 7Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30[J].Qual Life Res,2000,9(2) : 129-137.
  • 8Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL1 Trial)[J].J Clin Oncol, 2003, 21 (12): 2237- 2246.
  • 9Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial [J].JAMA, 2003, 290 (16): 2149-2158.
  • 10Herbst RS. Dose-comparative monatherapy trials of ZD1839 in previously treated non-small cell lung cancer patients [J]. Semin Oncol,2003,30(1 Suppl 1) : 30-38

共引文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部